Cynata Therapeutics Halts Trading Pending Clinical Trial Results
Key points
- Trading halt requested by Cynata Therapeutics
- Pending announcement of Phase 3 Osteoarthritis Trial and Phase 2 GvHD Trial results
- Halt will remain until announcement or June 16, 2026
Full summary
Cynata Therapeutics Limited (ASX: CYP) has requested a trading halt on its securities pending the release of clinical trial results for its Phase 3 Osteoarthritis Trial and Phase 2 Graft Versus Host Disease Trial. The halt will remain in effect until the earlier of the release of the announcement or the commencement of trading on June 16, 2026. The company has demonstrated positive safety and efficacy data for its Cymerus product candidates in previous trials and has ongoing trials for various indications.
Outlook
Cynata Therapeutics is awaiting the results of its clinical trials, which are expected to provide insights into the efficacy and safety of its Cymerus product candidates.
Summary generated by a large language model. Please interpret with care.